CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 23, 2006--Curis, Inc. (NASDAQ: CRIS - News), a therapeutic drug development company, today provided an update on a Phase I clinical trial for the treatment of basal cell carcinoma. This Phase I clinical trial is being conducted by Genentech (NYSE: DNA - News) and Curis, and is expected to be completed in the first half of 2006. At the conclusion of this Phase I clinical trial, Curis and Genentech plan to make a decision about whether to advance the drug candidate, a topical antagonist of the Hedgehog signaling pathway, into a Phase II clinical trial.
